Valo Therapeutics bags 19 million euros funding
Valo Therapeutics says it has successfully secured a financing round of 19 million euros ($20.6 million), part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer.
An investment round of 13 million euros was co-led by Indaco Venture Partners and CDP Venture Capital SGR with the support of Fondazione ENEA Tech e Biomedical. They join the completed 6 million euros investment round from Australian investors, supported by major shareholder Freeman Road, the investment entity of current Director Dr Paul Porter, bringing the total fundraising up to 19 million euros.
Will help fund Phase Ib clinical study of the company's lead compound
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze